一、担保情况及售后回租赁情况概述 证券代码：300511 证券简称：雪榕生物 公告编号：2024-042 债券代码：123056 债券简称：雪榕转债 上海雪榕生物科技股份有限公司 关于全资子公司开展售后回租赁业务 暨2023年度担保额度预计的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 （一）担保情况概述 上海雪榕生物科技股份有限公司（以下简称"公司"）于2023年7月31日召开了 第四届董事会第五十一次会议和第四届监事会第二十六次会议、于2023年8月23日召 开了2023年第三次临时股东大会，分别审议通过了《关于2023年度担保额度预计的 议案》。为满足公司及子公司生产经营和业务发展需要，确保资金流畅通，公司在 保证规范运营和风险可控的前提下，预计在2023年度为子公司向银行或其他金融机 构申请融资业务时提供总额度不超过人民币21.5亿元（含本数）的担保，其中，公司 为资产负债率低于70%的子公司提供担保额度为17.5亿元人民币（含本数），为资产 负债率高于70%的子公司提供担保额度为4.0亿元人民币（含本数），担保额度有效 期限自公司2023 ...

| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2024-038 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 关于召开 2023 年年度股东大会通知的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）第五届董事会第九次 会议审议通过了《关于召开 2023 年年度股东大会的议案》，决定于 2024 年 5 月17日召开公司2023年年度股东大会，现将本次股东大会的有关事项通知如下： 一、本次股东大会召开的基本情况 1、股东大会届次：2023 年年度股东大会。 2、股东大会召集人：公司董事会。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》等规定。 4、会议召开的日期、时间 5、会议的召开方式：本次股东大会采取现场表决与网络投票相结合的方式。 （1）现场投票：股东本人出席现场会议或通过授权委托他人出席现场会议； （2）网络投票：本次股东大会将通 ...

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-034 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于前期会计差错更正及追溯调整的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）于2024年4月25日召开 第五届董事会审计委员会第五次会议、第五届董事会第九次会议和第五届监事会 第七次会议，分别审议通过了《关于前期会计差错更正及追溯调整的议案》，同 意公司根据《企业会计准则第28号——会计政策、会计估计变更和差错更正》《公 开发行证券的公司信息披露编报规则第19号——财务信息的更正及相关披露》等 相关规定和要求，对公司前期会计差错进行更正并追溯调整相关年度的财务数 据。现将具体事项公告如下： 一、前期会计差错更正的原因及内容 （一）前期会计差错更正的原因 公司于2023年12月25日收到中国证券监督管理委员会上海监管局（以下简称 "上海证监局"）印发的《关于对上海雪榕生物科技股份有限公司采取责令改正措 施的决定 ...

Financial Performance - The company's operating revenue for the reporting period was ¥928,810,813.47, a decrease of 6.73% compared to ¥995,800,104.43 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥70,702,210.37, representing a decline of 145.48% from a profit of ¥155,466,147.74 in the previous year[4] - Basic and diluted earnings per share were both -¥0.16, a decrease of 144.44% compared to ¥0.36 in the previous year[5] Cash Flow - The net cash flow from operating activities was ¥51,797,697.21, down 80.88% from ¥270,882,499.62 in the same period last year[5] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,311,699,860.85, a decrease of 5.19% from ¥4,547,783,435.53 at the end of the previous year[5] - The net assets attributable to shareholders were ¥1,900,602,599.20, down 5.78% from ¥2,017,187,114.89 at the end of the previous year[5] - The company's asset-liability ratio was 55.97%, slightly up from 55.89% at the end of the previous year[11] Financial Ratios - The EBITDA interest coverage ratio was 2.38, down from 8.77 in the same period last year[11] Dividends and Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[1] - There were no changes in the controlling shareholder or actual controller during the reporting period[7]

Financial Performance - The company's total revenue for 2020 was ¥2,202,185,873.52, representing a 12.09% increase compared to ¥1,964,574,723.12 in 2019[26]. - The net profit attributable to shareholders for 2020 was ¥230,412,693.24, a 4.58% increase from ¥220,327,429.85 in 2019[26]. - The net cash flow from operating activities decreased by 5.36% to ¥555,465,789.24 in 2020 from ¥586,928,417.62 in 2019[26]. - The total assets at the end of 2020 were ¥4,547,783,435.53, an 18.37% increase from ¥3,841,850,151.29 at the end of 2019[26]. - The net assets attributable to shareholders increased by 15.90% to ¥2,017,187,114.89 at the end of 2020 from ¥1,740,475,998.42 at the end of 2019[26]. - The basic earnings per share for 2020 was ¥0.53, up 3.92% from ¥0.51 in 2019[26]. - The diluted earnings per share for 2020 was ¥0.54, a 5.88% increase from ¥0.51 in 2019[26]. - The company reported a quarterly revenue of ¥638,713,309.32 in Q4 2020, showing a strong performance compared to previous quarters[29]. - The company received government subsidies amounting to ¥27,886,368.45 in 2020, which was primarily related to its subsidiary[32]. - The company reported a total distributable profit of RMB 639,642,807.27 for the year[121]. Production and Capacity - The company reported a significant increase in production capacity, leading to intensified competition in the edible mushroom market, which may result in a downward pressure on product prices[6]. - The company has a daily production capacity of 1,325 tons of edible mushrooms, with enoki mushrooms accounting for 1,000 tons, ranking first in the country[45]. - The production capacity of subsidiary companies for king oyster mushrooms and other varieties has been further released, leading to an increase in edible mushroom production and sales volume[40]. - The company has established seven major production bases across China and is constructing additional bases in Hubei and Anhui, enhancing its national layout[45]. - The company has invested in comprehensive edible mushroom factories in various regions, including Shanghai, Jilin, and Thailand, promoting mechanized and standardized production[36]. Market and Sales - The company operates a sales model primarily through distributors, with direct sales to supermarkets, chain restaurants, and fresh delivery platforms[40]. - The edible mushroom sector accounted for ¥2,179,627,097.78, or 98.98% of total revenue, with a year-on-year growth of 12.01%[66]. - The sales of enoki mushrooms generated ¥1,625,784,212.05, making up 73.83% of total revenue, with a growth of 5.66% from the previous year[66]. - Domestic sales contributed ¥2,164,250,122.84, which is 98.28% of total revenue, reflecting an increase of 11.41% year-on-year[63]. - The company has diversified its marketing strategies, increasing its presence in major retail chains and e-commerce platforms[56]. Research and Development - Research and development expenses rose by 8.38% to ¥11,850,052.26, indicating ongoing investment in technology and product development[76]. - The company is focusing on the research and development of new strains and varieties to ensure stable production and improve product quality[112]. - The company has a strategic focus on the "plant-based meat" sector, with ongoing research and development efforts[118]. - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for the development of new technologies and products in 2021[166]. Risk Management - The company anticipates potential risks of declining gross margins due to increased competition and price reductions in the edible mushroom market, alongside challenges in overseas operations[9]. - The main raw materials for production include rice bran, corn husks, and other agricultural by-products, which are subject to price volatility and quality fluctuations that could impact production costs[10]. - Management risks associated with business expansion are being addressed through the implementation of a partner mechanism to improve management efficiency and team motivation[12]. Investment and Expansion - The company has signed investment agreements to build new production bases in Hubei and Anhui, further consolidating its market position[57]. - The company has established new subsidiaries in Thailand and China in 2020, reflecting the company's strategy for market expansion[71]. - The company is actively seeking investment opportunities and potential mergers and acquisitions in the edible mushroom industry to explore new growth avenues[112]. Cash Dividends and Shareholder Returns - The company has proposed a cash dividend of 1.2 RMB per 10 shares, based on a total of 442,029,925 shares[13]. - The cash dividend amount for 2020 was 53,043,591.0, representing 23.02% of the net profit attributable to ordinary shareholders[125]. - The cash dividend represents 100% of the total profit distribution for the year[121]. - The company plans to distribute cash dividends amounting to no less than 20% of the distributable profit achieved in the current year[159]. Compliance and Governance - The company has not classified any non-recurring gains as recurring gains in its financial reporting[33]. - The company has not experienced any major litigation or arbitration matters during the reporting period[183]. - The company has not engaged in any related party transactions during the reporting period[186]. - The company has a commitment to not transfer shares exceeding 25% of their total holdings during their tenure[126]. Sustainability and Future Outlook - The company emphasizes the importance of reasonable returns to investors while ensuring sustainable development[158]. - A commitment to sustainability has been made, with plans to reduce carbon emissions by 15% over the next three years[141]. - The company plans to enhance its marketing network and develop new edible mushroom products to strengthen its competitive edge[110]. - Looking ahead, the company has provided guidance for 2021, projecting a revenue growth of 30% to 1.56 billion yuan[140].

二、财务状况、经营成果和现金流量情况分析 上海雪榕生物科技股份有限公司 2023 年度财务决算报告 根据上海雪榕生物科技股份有限公司截止 2023 年 12 月 31 日的财务状况和 2023 年度的经营成果和现金流量，结合公司实际运营中的具体情况，我们进行 了认真的研究分析，现将公司有关的财务决算情况汇报如下： 一、2023 年公司财务报表审计情况 公司 2023 年财务报表已经安永华明会计师事务所（特殊普通合伙）审计， 出具了安永华明（2024）审字第 70009152_B01 号标准无保留意见审计报告。会 计师的审计意见是：公司财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了上海雪榕生物科技股份有限公司 2023 年 12 月 31 日的合并及公司财 务状况以及 2023 年度的合并及公司经营成果和现金流量。 （一）资产情况： | 单位：万元 | | --- | | 项目 | 2023 | 年 12 | | 年 2022 12 | 同比增减 | 占总资产比重 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 月 31 日 | ...

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-033 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于2024年度担保额度预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别风险提示： 公司提供担保总额超过公司最近一期经审计净资产100%、对资产负债率超过70% 的子公司担保金额超过公司最近一期经审计净资产50%。不存在公司及子公司对合 并报表范围外的其他第三方提供的对外担保，亦无逾期担保、涉及诉讼及因担保被 判决败诉而应承担担保等情况。请投资者充分关注担保风险。 上海雪榕生物科技股份有限公司（以下简称"公司"）于2024年4月25日召开了 第五届董事会第九次会议和第五届监事会第七次会议，审议通过了《关于2024年度 担保额度预计的议案》，现将具体情况公告如下： 一、担保情况概述 为满足公司及子公司生产经营和业务发展需要，确保资金流畅通，公司在保证 规范运营和风险可控的前提下，预计在2024年度为子公司向银行或其他金融机构申 请融资业务时提供总额度不 ...

2023 年度独立董事述职报告 上海雪榕生物科技股份有限公司 一、独立董事的基本情况 各位股东及股东代表： 本人刘浩，在2023年度任职上海雪榕生物科技股份有限公司（以下简称"公 司"）独立董事期间，严格按照《公司法》《深圳证券交易所上市公司自律监管 指引第2号——创业板上市公司规范运作》等法律法规、规范性文件以及《公司 章程》《公司独立董事工作制度》的规定和要求，认真、勤勉、独立的履行独立 董事职责，主动了解公司的生产经营运作情况，积极出席公司召开的相关会议， 认真审议董事会的各项议案，充分发挥了独立董事的独立性、专业性的作用，切 实维护了公司和全体股东尤其是中小股东的合法权益。现将本人2023年度任职期 间履行独立董事职责情况汇报如下： （一）个人工作履历、专业背景等情况 刘浩，男，1978年11月生，中国国籍，无境外永久居留权，博士学历，教授 职称。曾任上海财经大学会计学院讲师、副教授，美国纽约城市大学访问学者， 2017年8月至2023年8月任公司独立董事。现任上海财经大学会计学院教授、博士 生导师，财政部第四届企业会计准则咨询委员会委员。兼任上海肇民新材料科技 股份有限公司、湖北回天新材料股份有限公 ...

最近几年，食用菌市场竞争愈发激烈。2021 年至 2022 年上半年度，受大宗 货物贸易影响，工厂化食用菌产品单位成本上升明显，同时需求端不景气，食用 菌行业整体行情下行，食用菌行业盈利能力普遍下降，不少工厂化企业停产、转 产或是减产，截止 2021 年 12 月，全国食用菌工厂化生产企业共有 337 家，企业 数量较 2019 年的 417 家减少了 80 家，同比减少幅度接近 20%。受供给端变化以 及 2023 年一季度消费市场回暖等因素的影响，食用菌产品在 2022 年三季度至 2023 年一季度期间维持了较长时间的高价格，因此行业内部分公司尤其是拥有 技术优势、规模优势、品牌优势的规模化食用菌工厂化企业在报告期内加速扩充 产能，提升市场占有率。报告期内，公司广西贵港基地"年产 12 万吨食用菌现 代农业产业园项目（一期）"和江苏淮安基地"雪榕现代食品产业项目（一期）" 以及同行业上市公司江苏华绿生物科技股份有限公司（300970）广西崇左基地"现 代农业食用菌工厂化项目（一期）"和河北华绿之珍生物技术有限公司"年产 5.4 万吨鲜品金针菇工厂化生产项目"、福建万辰生物科技集团股份有限公司 （3009 ...

Financial Performance - The company's revenue for Q3 2021 was ¥500,488,155.72, a decrease of 11.84% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥44,687,522.97, representing a decline of 173.06% year-on-year[3]. - The basic earnings per share were -¥0.10, a decline of 171.43% year-on-year[3]. - Net profit for Q3 2021 was a loss of ¥143,764,632.81, compared to a profit of ¥202,162,091.60 in Q3 2020, indicating a significant decline in profitability[24]. - Total operating revenue for Q3 2021 was ¥1,429,298,969.19, a decrease of 8.56% compared to ¥1,563,472,564.20 in Q3 2020[23]. - Total operating costs increased to ¥1,595,828,968.08, up 15.5% from ¥1,382,054,183.68 in the previous year[23]. - Total comprehensive income for the period was -155,792,313.28 CNY, compared to 195,597,027.22 CNY in the previous period[25]. - Basic and diluted earnings per share were both -0.27 CNY, down from 0.50 CNY and 0.48 CNY respectively in the previous period[25]. Cash Flow and Assets - The net cash flow from operating activities was ¥70,975,793.40, down 80.38% from the previous year[3]. - Cash flow from operating activities generated a net amount of 70,975,793.40 CNY, a significant decrease of 80.4% from 361,815,630.31 CNY in the previous period[28]. - Cash inflow from operating activities totaled 1,476,896,148.38 CNY, down 7.7% from 1,600,004,130.22 CNY in the previous period[28]. - Cash outflow from operating activities was 1,405,920,354.98 CNY, an increase of 13.5% compared to 1,238,188,499.91 CNY in the previous period[28]. - The cash and cash equivalents decreased to ¥312,370,296.71 from ¥759,891,920.58, a decline of 58.9%[20]. - The ending balance of cash and cash equivalents was 310,782,975.99 CNY, down 59.8% from 772,823,507.02 CNY in the previous period[29]. - Current assets totaled ¥910,065,869.52, down 26% from ¥1,228,373,292.27 at the end of 2020[20]. - The company's total assets decreased to ¥4,431,397,663.39 from ¥4,547,783,435.53 at the end of 2020, reflecting a reduction of approximately 2.6%[21]. - Total liabilities rose to ¥2,593,819,338.00, an increase of 2.1% from ¥2,541,797,703.73[21]. - Total liabilities amounted to CNY 2,541,797,703.73, with a slight increase of CNY 20,885,261.24 compared to the previous period[33]. - Current liabilities totaled CNY 1,385,109,958.90, reflecting a decrease of CNY 2,164,248.63 from the previous period[33]. - Non-current liabilities reached CNY 1,156,687,744.83, showing an increase of CNY 18,721,012.61 compared to the last report[33]. Shareholder Information - The equity attributable to shareholders decreased by 8.66% to ¥1,842,497,440.19 compared to the end of the previous year[4]. - The company reported a total of 33,271,375 shares held by the largest shareholder, Yang Yongping, representing a significant portion of the total shares[17]. - The company has a total of 126,178,519 restricted shares at the beginning of the period, with 50,000 shares released during the period[17]. - The company completed the repurchase and cancellation of certain restricted shares on July 29, 2021, without adjusting the conversion price of the convertible bonds[15]. - The company received approval from the China Securities Regulatory Commission for a stock issuance to specific investors on March 24, 2021[15]. - The company is actively pursuing market expansion and strategic initiatives as indicated by its stock issuance plans[14]. - The company has engaged in financing and securities lending activities with its top shareholders, although no specific details were provided[13]. - The company has not reported any related party transactions or concerted actions among its major shareholders[17]. Investment and Expenses - The company reported a significant increase in construction in progress, rising by 88.53% to ¥230,113,403.60 due to new project investments[8]. - The company experienced a 73.61% increase in cash outflow from investing activities, totaling -¥524,884,769.11, primarily due to project construction investments[9]. - The company reported a significant increase in research and development expenses to ¥12,437,740.95, up 29.4% from ¥9,584,250.06 in the previous year[24]. - The company reported a significant increase in payments to employees, totaling 363,377,706.94 CNY, up 16.5% from 311,928,178.12 CNY in the previous period[28]. - The company reported CNY 250,318,751.65 in other payables, which includes various liabilities[33]. - The capital reserve stands at CNY 484,218,723.66, unchanged from the previous period[34].